Studies of TNF-blockers in patients with IBD are pregnant use these drugs in autoimmune diseases like rheumatoid arthritis The, psoriatic arthritis, juvenile idiopathic arthritis and ankylosing spondylitis. Many studies of anti-TNF-alpha in pregnancy on patients with rheumatoid arthritis Of. These studies are retrospective, registry studies or case reports. In 2007, Roux et al. pr sentierten their experiences with three patients with rheumatoid arthritis who became pregnant, w while with anti-TNF-alpha. One patient terminated her pregnancy, but there were no known complications may need during the pregnancy or fetal health, and two pass infants.93 recently told the British Society for Rheumatology Biologics Register, an hour Streptozotocin Zanosar Rate of abortion here spontaneously in patients on TNF blockers of conception, compared with 17% of spontaneous abortions among those with prior exposure to TNF-blockers, and 10% of abortions in the control group. They suggested that these drugs be avoided in the design, although no definitive conclusions can be drawn during pregnancy on the safety of anti-TNF drugs w K. In the first big s series of infliximab in 96 women with RA and CD, Katz et al. the database is queried and safety of infliximab showed that the outcomes of pregnancies in women exposed directly to infliximab similar to the general Bev Lkerung the United States in terms of live births, miscarriages and therapeutic termination.95 was in a series of pilot relooking infliximab w during pregnancy in 10 patients with CD, Mahadevan et al.
showed good results without congenital malformations, dir siege intrauterine growth or small for gestational S uglinge. However, there were three S Uglinge too soon, and we have reported low birth weight.96 other case reports and small case series, the application may need during the pregnancy IFX in IBD patients have no congenital malformations, but the children were premature, or for gestational age 101 age.97 A recent small observational study, the outcome of pregnancy in 212 women with IBD with anti-TNF therapies, 42 pregnancies in women who have evaluated re-treated u anti-TNF, 23 pregnancies before the diagnosis of IBD, 78 pregnancies Aldosterone before the start of IFX, 53 pregnancies with an indirect exposure to IFX pregnancies and 56 matched healthy women. They found that pregnancies after exposure to anti-TNF therapy is not different than before anti-TNF treatment, but they were worse than before MII from diagnosis.99 Until the recent review of the program risks mother in Canada102 and the opinion of London the World Congress of Gastroenterology guideline102 consensus view, 103 infliximab at low risk of fetal and be compatible with use in the construction of at least a first and second quarters. No studies have been obtained one HTES risk for embryo-toxicity T, Teratogenit t or adverse pregnancy outcome in patients treated with TNF-blockers showed therapy.104 is, however, the use of IFX until week 30 of pregnancy causes fetal intrauterine exposure to high concentrations of IFX, increases hen is worried about the long-term effects of IFX on children of women with IBD to IFX.105 The authors recommend that such therapy after 30 weeks of pregnancy, if m be avoided possible. In particular, care must be taken when the vaccination for S Uglinge one.